Medscape, LLC is pleased to provide online continuing medical education (CME) for this journal article, allowing clinicians the opportunity to earn CME credit. Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide CME for physicians. Medscape, LLC designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation at http://www.medscape.com/cme/eid; (4) view/print certificate.

Learning Objectives

Upon completion of this activity, participants will be able to:

• Identify properties of Alcaligenes xylosoxidans.
• Describe the clinical presentation of A. xylosoxidans infection in the current study.
• Specify risk factors for infection with A. xylosoxidans.
• Identify the primary source of infection with A. xylosoxidans in the current study.

Editor

D. Peter Drotman, MD, Editor-in-Chief, Emerging Infectious Diseases. Disclosure: D. Peter Drotman, MD, has disclosed no relevant financial relationships.

CME Author

Charles P. Vega, MD, Associate Professor; Residency Director, Department of Family Medicine, University of California, Irvine. Disclosure: Charles P. Vega, MD, has disclosed that he has served as an advisor or consultant to Novartis, Inc.

Authors

Disclosures: Moon Kim, MD, MPH; Elizabeth Bancroft, MD, SM; Eleanor Lehnkering, MS; and Rodney M. Donlan, PhD, have disclosed no relevant financial relationships. Laurene Mascola, MD, MPH, has disclosed that she has served has an advisor or consultant to Merck and MedImmune. Dr. Mascola has also disclosed that she has served as a speaker for Merck.